February 21, 2025
Dear Colleagues and Friends, The Cooperative Groups that come together in the National Clinical Trials Network (NCTN) are responsible for a number of significant advances in cancer treatment arising over the past 40 years. In that time, as published by Unger et al (J Clin Oncol, 2023), this research has led to an estimated 14 million life-years saved for patients with cancer,
February 6, 2025
Dean Shumway, MD, of Mayo Clinic, leads this phase III trial that compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the
February 5, 2025
Alliance A032201 - Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE Bradley McGregor, MD, of Dana-Farber Cancer Institute, leads this phase III trial that compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal a
